GLYC News and Press, GlycoMimetics Inc. From 02/22/23

Shares of clinical-stage biotech GlycoMimetics ( NASDAQ: GLYC ) lost ~6% pre-market Wednesday after the company announced the resignation of its co-founder and Chief Scientific Officer, Dr. John Magnani, effective Mar. 31. The departure follows an agreement between GlycoMimetics (...

Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports and conference presentations. ...

Summary Today, we take a look at a small biopharma concern called GlycoMimetics that is focused on developing treatments for disease through the inhibition of a subset of proteins known as selectins. The stock plunged more than 50% earlier this week on news of a capital raise and key tr...

GlycoMimetics, Inc. (the “Company”) (NASDAQ:GLYC) today announced that the Compensation Committee of the Company’s Board of Directors approved the grant on February 10, 2023 of a non-qualified stock option award to purchase an aggregate of 150,000 shares to Chinmaya Rath, the...

Clinical-stage biotech GlycoMimetics ( NASDAQ: GLYC ) lost ~40% pre-market Wednesday after announcing that the company sold ~11.8M shares of its common stock in an “at-the-market” offering throughout Q4 2022. The company said the capital raise would extend its cash runwa...

Independent Data Monitoring Committee recommended pivotal Phase 3 study continue to the originally planned final overall survival events trigger and expressed no concerns about safety Interim utility analysis was conducted using a very high statistical threshold to preserve the integrity of t...

January’s CPI inflation report is out, and investors have begun digesting the data in the stock market today. Whether you’re trading penny stocks or not, it likely comes secondary to what information was released. Both CPI and Core CPI inflation numbers came in above expectation...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips The stock market got crushed in 2022. It was a nasty year for most investors.  But what if I told you that amid 2022’s financial market turmoil, there was a quantitative trading system that was regularly pi...

Summary GlycoMimetics may have discovered a successful treatment for AML leukemia, currently with a 5-year survival rate of around 30%. Small research trial sizes have delivered exceptional results, with the U.S. FDA engaging in an Interim Utility Analysis of the company's uproleselan P...

Whether you’re looking for the best penny stocks to buy now or just putting together a watch list, research is the first place to begin. Understanding why specific stocks are moving the way they are can help when applying your trading strategy to the stock market today. That’s b...